
This Week’s Biopharma News: Argentina’s WHO Exit and Sanofi Acquisition of Blueprint Medicines
Credit: Roche Sanofi to Acquire Blueprint Medicines Sanofi intends to acquire Blueprint Medicines in a transaction valued at up to $9.5 billion, comprising $129.00 per share in cash and a contingent value right of up to $6.00 per share tied to regulatory …